Last updated: March 13, 2026
What is the Drug NDC 43598-0901?
The NDC 43598-0901 corresponds to Lenalidomide marketed primarily by Celgene (now part of Bristol-Myers Squibb). It is indicated for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, among other hematologic conditions. The drug is available as capsules, typically in a 15 mg dose.
Market Landscape
Market Size and Adoption
- Global Hematologic Disease Market: Estimated at $10 billion in 2023, with key drivers including increased incidence of multiple myeloma and expanding indications for lenalidomide.
- Market Penetration:
- North America accounts for roughly 50% of sales.
- Europe contributes about 30%.
- Asia-Pacific approximates 15%, expected to grow with increased healthcare access.
- Patient Population:
- Multiple myeloma: Approx. 160,000 diagnosed cases globally.
- MDS: Approx. 117,000 cases worldwide.
Competitive Landscape
- Key Competitors:
- Pomalidomide (Imnovid, Celgene/BMS)
- Thalidomide (Thalomid, Celgene/BMS)
- Newer agents like Iberdomide and CC-92480 entering clinical trials.
- Market Share:
- Lenalidomide maintains roughly 70% of the hematologic oncology drug market share within its class.
- Growth driven by combination therapies and expanded indications.
Regulatory Status
- Widely approved in the U.S., EU, and Japan.
- Patent expiry approaching or passed in several jurisdictions, opening opportunities for generics.
Pricing Analysis
Current Pricing
- Brand Name (Revlimid by BMS): Approximate wholesale acquisition cost (WAC) of $16,000 per 28-day supply (30 capsules of 15 mg).
- Generic Versions: Entering markets at prices ranging from $8,000 to $12,000 per 28-day supply, depending on jurisdiction and manufacturer.
Reimbursement and Access
- U.S. Medicare and Medicaid: Price negotiations influence net pricing.
- Private Insurance: Coverage varies, with co-payments typically around 20% to 30%.
Price Trends
- Patent expiration expected within 2 years in the U.S., leading to increased generic competition.
- Historical case: Imatinib (Gleevec) experienced a 60% price drop post-patent expiry.
Price Projections (Next 5 Years)
| Year |
Scenario |
Estimated Price (per 28-day supply) |
Key Drivers |
| 2023 |
Current |
$16,000 (brand) |
Patent expiry uncertainty, ongoing demand |
| 2024 |
Moderate generic entry |
$12,000 |
Market access expands, pricing pressure increases |
| 2025 |
Increased generic market share |
$9,000 |
Generics reach >50% of prescriptions, price erosion |
| 2026 |
Widespread generics |
$7,000 |
Price competition stabilizes |
| 2027 |
Post-patent period |
$5,000 |
Dominance of generics, biosimilar activity |
Market Risks and Opportunities
- Risks:
- Patent cliffs accelerate generic entry, reducing revenue.
- Regulatory delays or restrictions.
- Emergence of alternative therapies.
- Opportunities:
- Expanded indications for less established conditions.
- Development of biosimilars and interchangeable formulations.
- Partnerships for combination therapies.
Summary
Lenalidomide (NDC 43598-0901) exhibits a robust market driven by its positioning in hematology. Pricing remains high in the absence of generics but is poised for significant decline following patent expiration. The market is characterized by high unmet needs that sustain demand, although pricing pressures will intensify in the coming years.
Key Takeaways
- The drug's revenue is highly sensitive to patent status and generic competition.
- Current prices are around $16,000 per 28-day supply.
- Post-patent expiry, prices are projected to decline to approximately $5,000.
- Market growth continues, especially in emerging jurisdictions.
- Competition from biosimilars and newer agents will influence future pricing strategies.
FAQs
1. When does patent expiry for Lenalidomide occur?
Patent protections are expected to expire around 2024 in the U.S., enabling generic manufacturing.
2. How does generic entry impact pricing?
Generics typically reduce prices by 40% to 60%, depending on market dynamics and regulatory approval.
3. What are the primary markets for this drug?
The U.S., Europe, and Japan constitute the largest markets, with Asia-Pacific showing growth potential.
4. Are biosimilars relevant for Lenalidomide?
Lenalidomide is a small-molecule drug, making biosimilar development less applicable. However, future combination treatments could introduce similar biological agents.
5. What are the main drivers of demand growth?
Increasing incidence of multiple myeloma and expanded indications contribute to sustained high demand.
References
- Statista. (2023). Hematologic disease market size.
- EvaluatePharma. (2023). Oncology drug pricing and market analysis.
- US Food and Drug Administration. (2022). Patent expiration timeline for Revlimid.
- IQVIA. (2023). Global prescription drug sales data.
- European Medicines Agency. (2022). Regulatory status of lenalidomide.
